We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





New High-Throughput RT-PCR Testing System for SARS-CoV-2 Can Process Up to 35,000 Tests per Day

By LabMedica International staff writers
Posted on 01 Dec 2020
Testing labs can now leverage a new high-throughput (HTP) RT-PCR testing system for SARS-CoV-2 that can expand capacity by running up to 35,000 tests per day.

LGC Genomics (Middlesex, UK) has submitted its HTP RT-PCR testing system for SARS-CoV-2 to the FDA for Emergency Use Authorization (EUA). More...
As the need for SARS-CoV-2 testing continues to grow for both diagnostic and screening applications, many organizations are looking to expand or create testing capacity. For existing diagnostic labs, limited supplies of instruments, reagents and laboratory technologists make getting high volumes of testing done in a timely manner challenging.

With the HTP RT-PCR testing system for SARS-CoV-2, EUA request submitted, testing labs can leverage LGC's expertise in automated sample preparation and RT-PCR workflows in a ready-to-deploy sample-to-answer solution. LGC’s SARS-CoV-2 testing workflow is an optimized hardware, reagents, consumables, and software bundle that includes the high-throughput oKtopure automated nucleic acid extraction system, the footprint-friendly IntelliQube (qPCR) and Hydrocycler2 (end-point PCR) platforms, Biosearch Technologies’ validated SARS-CoV-2 reagents, enzymes, and probe and primer sets, and UgenTec’s AI-powered workflow automation, PCR analysis and reporting software. Testing capacity can be expanded from hundreds or thousands of samples to as many as 35,000 samples per day with minimal need for additional staff, instrumentation, or lab space.

"Limited supplies of instruments, reagents and laboratory technicians have made it challenging to deliver high volumes of testing in a timely manner," said Mark Dearden, Managing Director, LGC Genomics. "The creation of new facilities and conversion of research labs into testing labs introduces the complexities of creating new, regulatory-compliant workflows. Our solution can enhance testing strategies and ramp up throughput of testing per day. If used widely, our ability to support large-scale testing could lead to enhanced management of virus response, which ultimately could unlock safe returns to work and get economies moving once again."

Related Links:
LGC Genomics


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The study identified a distinct immune signature associated with treatment-resistant myasthenia gravis (Dodd, Katherine C. et al., Med (2026). DOI: 10.1016/j.medj.2025.100987)

Immune Signature Identified in Treatment-Resistant Myasthenia Gravis

Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.